Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS)
- ACS Med Chem Lett. 2010 Feb 2;1(2):59-63. doi: 10.1021/ml900025z.
- 1. Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017.
- 2. Department of Research, Mount Sinai Medical Center, 4300 Alton Road, Miami Beach, Florida 33140.
Hematopoietic Prostaglandin D Synthase (HPGDS) is primarly expressed in mast cells, antigen-presenting cells, and Th-2 cells. HPGDS converts PGH2 into PGD2, a mediator thought to play a pivotal role in airway allergy and inflammatory processes. In this letter, we report the discovery of an orally potent and selective inhibitor of HPGDS that reduces the antigen-induced response in allergic sheep.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: PGE synthaseResearch Areas: Inflammation/Immunology
-
Research Areas: Inflammation/Immunology